Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued access study of efanesoctocog alfa in patients completing a previous trial
NL-OMON60887Phase 3Completed
- Sponsor
- Sobi
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sobi. Primary endpoints: Safety and tolerability, Prophylactic efficacy and 1 more. Started Mar 2024; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON60887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60887.